Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Higgins

Showing results (241-250 of 283) with videos related to

Pageof 29
Sort By:
Journal of Crohn'S & Colitis|March 2, 2016
European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's DiseaseFlorian Rieder, Giovanni Latella, Fernando Magro, et al.
Research Square|April 27, 2026
Navigating Treatment Selection in Acute Severe Ulcerative Colitis: A Prospective Mixed Method Analysis of Factors Influencing Patient Decision MakingReid Herran, Samuel Wilcox, Gal Hodish, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trialsDavid T Rubin, Iris Dotan, Aaron DuVall, et al.
Cellular and Molecular Gastroenterology and Hepatology|November 1, 2016
Functional Characterization of Inflammatory Bowel Disease-Associated Gut Dysbiosis in Gnotobiotic MiceHiroko Nagao-Kitamoto, Andrew B Shreiner, Merritt G Gillilland, et al.
Gastrointestinal Endoscopy|December 21, 2014
The risk of post-ERCP pancreatitis and the protective effect of rectal indomethacin in cases of attempted but unsuccessful prophylactic pancreatic stent placementNeel S Choksi, Evan L Fogel, Gregory A Cote, et al.
The American Journal of Gastroenterology|June 25, 2025
A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the PouchEdward L Barnes, Laura Raffals, Taha Qazi, et al.
Gut|February 18, 2017
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trialsJulian Panés, William J Sandborn, Stefan Schreiber, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 12, 2020
Coronavirus Disease 2019 (COVID-19) Clinical Trial Oversight at a Major Academic Medical Center: Approach of Michigan MedicineKayte Spector-Bagdady, Peter D R Higgins, Keith D Aaronson, et al.
The Lancet. Gastroenterology & Hepatology|September 8, 2023
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance studySéverine Vermeire, Silvio Danese, Wen Zhou, et al.
Journal of Crohn'S & Colitis|February 5, 2019
CD4+ Tissue-resident Memory T Cells Expand and Are a Major Source of Mucosal Tumour Necrosis Factor α in Active Crohn's DiseaseShrinivas Bishu, Mohammed El Zaatari, Atsushi Hayashi, et al.
Pageof 29

Showing results (241-250 of 283) with videos related to

Sort By:
Pageof 29
Journal of Crohn'S & Colitis|March 2, 2016
European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's DiseaseFlorian Rieder, Giovanni Latella, Fernando Magro, et al.
Research Square|April 27, 2026
Navigating Treatment Selection in Acute Severe Ulcerative Colitis: A Prospective Mixed Method Analysis of Factors Influencing Patient Decision MakingReid Herran, Samuel Wilcox, Gal Hodish, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trialsDavid T Rubin, Iris Dotan, Aaron DuVall, et al.
Cellular and Molecular Gastroenterology and Hepatology|November 1, 2016
Functional Characterization of Inflammatory Bowel Disease-Associated Gut Dysbiosis in Gnotobiotic MiceHiroko Nagao-Kitamoto, Andrew B Shreiner, Merritt G Gillilland, et al.
Gastrointestinal Endoscopy|December 21, 2014
The risk of post-ERCP pancreatitis and the protective effect of rectal indomethacin in cases of attempted but unsuccessful prophylactic pancreatic stent placementNeel S Choksi, Evan L Fogel, Gregory A Cote, et al.
The American Journal of Gastroenterology|June 25, 2025
A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the PouchEdward L Barnes, Laura Raffals, Taha Qazi, et al.
Gut|February 18, 2017
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trialsJulian Panés, William J Sandborn, Stefan Schreiber, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 12, 2020
Coronavirus Disease 2019 (COVID-19) Clinical Trial Oversight at a Major Academic Medical Center: Approach of Michigan MedicineKayte Spector-Bagdady, Peter D R Higgins, Keith D Aaronson, et al.
The Lancet. Gastroenterology & Hepatology|September 8, 2023
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance studySéverine Vermeire, Silvio Danese, Wen Zhou, et al.
Journal of Crohn'S & Colitis|February 5, 2019
CD4+ Tissue-resident Memory T Cells Expand and Are a Major Source of Mucosal Tumour Necrosis Factor α in Active Crohn's DiseaseShrinivas Bishu, Mohammed El Zaatari, Atsushi Hayashi, et al.
Pageof 29